Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • The Long Term Strategy For VistaGen Therapeutics (VSTA) 0 comments
    Dec 10, 2012 2:38 PM | about stocks: VSTA

    VistaGen Therapeutics is focused primarily on the use of its proprietary pluripotent stem cell technology to discover, rescue, and develop novel drug candidates for a wide range of diseases. The idea is to generate new chemical variants of once-promising small molecule drug candidates that pharmaceutical companies have put on hold during preclinical or early clinical trials due to heart or liver toxicity. Simply put: the drugs were effective but had some toxic side effects.

    The company's stem cell technology platform, Human Clinical Trials in a Test Tube, is based on the differentiation of human pluripotent stem cells into multiple types of mature cells which can then be used in drug testing for superior predictive toxicity, enabling better drug rescue and development. The platform was developed to determine toxicity with greater flexibility, speed, and precision than technologies currently in use by the pharmaceutical industry.

    VistaGen's overall strategy is to develop a rich pipeline of drug rescue variants, proprietary new small molecule drug candidates that are as effective as the original drug candidates but without the toxicity that caused them to be shelved. VistaGen plans to do this in collaboration with contract drug development service firms.

    Using the large amount of information in the public domain, VistaGen has identified numerous potential drug rescue candidates and is now focused on launching one or more drug rescue campaigns within the next three months. VistaGen plans to have economic participation rights to each and every drug it develops, benefitting its bottom line as well as its shareholders. The fact that the pharmaceutical industry is facing a major drug development crisis, largely due to the high cost of drug failures when toxicity and metabolism issues surface, VistaGen's planned drug rescue strategy could be of especially significant long-term value.

    For additional information, visit www.VistaGen.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: VSTA
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.